Healthy Volunteers
Conditions
Interventions
investigational material(s)
Generic name etc : TAK-438ASA, TAK-438, Aspirin
INN of investigational material : Vonoprazan, acetylsalicylic acid
Therapeutic category code : 339 Other agents relating to
Sponsors
Takeda Pharmaceutical Company Limited
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. In the opinion of the investigator or sub-investigator, participants are capable of understanding the procedures required for the study and complying with its requirements 2. Participants sign and date an informed consent form by themselves prior to the initiation of any study procedures 3. Japanese healthy men aged >= 20 and == 50 kg as well as body mass index (BMI) >= 18.5 kg/m^2 and =< 25.0 kg/m^2 at screening test
Exclusion criteria
Exclusion criteria: 1. Participants who received study drug within 16 weeks (112 days) prior to the start of study treatment in Period 1 2. Participants who received TAK-438 or aspirin in a previous study 3. Staffs at the study site and their family, or participants who depend on the study-related staffs at the study site (e.g., husband and wife, parents, children, brothers and sisters), or participants who may be constrained to consent to the study 4. Participants with uncontrolled and clinically significant neurological, cardiovascular, lung, hepatic, renal, metabolic, gastrointestinal, urinary or endocrine disease, or other abnormalities (except for diseases investigated) that might affect the study participation or impact the results of the study 5. Participants with a previous or current history of aspirin asthma (asthmatic attack induced by non-steroidal anti-inflammatory drugs, etc.) 6. Participants with hypersensitivity for components of TAK-438 tablet or aspirin enteric-coated tablet, or salicylic acid-based products 7. Positive result in urinary test for illegal drug abuse at screening 8. Participants who have a history of illegal drug abuse or alcoholism within the past 2 years prior to the screening visit, or who are not willing to refrain from alcohol consumption and drug use during the study period 9. Participants who ingested a medicine, a supplement or food forbidden to be used in combination during the specified time period. 10. Participants with a current history or recent episodes (within the past 6 months) of gastrointestinal diseases (malabsorption, gastroesophageal reflux, peptic ulcer disease, erosive oesophagitis), frequent (at least once per week) heartburn or surgical intervention that might affect drug absorption 11. Participants with a history of cancer, except for basal cell carcinoma in remission for >= 5 years prior to Day 1 12. Positive results at screening for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, or serological test for syphilis 13. Participants who have difficulties in blood draw from peripheral veins 14. Participants who had >= 200 mL of whole blood drawn within 4 weeks (28 days) prior to the start of study treatment in Period 1 or who had >= 400 mL of whole blood drawn within 12 weeks (84 days) prior to the start of study treatment in Period 1 15. Participants who had a total of >= 800 mL of whole blood drawn within 52 weeks (364 days) prior to the start of study treatment in Period 1 16. Participants who had blood components drawn within 2 weeks (14 days) prior to the start of study treatment in Period 1 17. Clinically significant abnormalities in electrocardiogram at screening or admission (Day -1) 18. Participants with abnormal laboratory parameters suggestive of clinically significant underlying diseases or who have abnormal values in the following measures at screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) over the upper limit of normal 19. Participants who are unlikely to comply with the protocol or deemed ineligible due to other reasons by the principal investigator or other investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pharmacokinetics Study 1, AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438-F) Time Frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose pharmacokinetics Study 1, Cmax: Maximum Observed Plasma Concentration for TAK-438F Time Frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose pharmacokinetics Study 1, AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin Time Frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose pharmacokinetics Study 1, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin Time Frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose | — |
Secondary
| Measure | Time frame |
|---|---|
| pharmacokinetics Study 1, AUC(infinity): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-438F Time Frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose pharmacokinetics Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F Time Frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose pharmacokinetics Study 1, MRT(infinity, ev): Mean Residence Time from Time 0 to Infinity for TAK-438F Time Frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose pharmacokinetics Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for TAK-438F Time Frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose pharmacokinetics Study 1, AUC(infinity): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Unchanged Aspirin Time Frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose pharmacokinetics Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin Time Frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose pharmacokinetics Study 1, MRT(infinity, ev): Mean Residence Time from Time 0 to Infinity for Unchanged Aspirin Time Frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose pharmacokinetics Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for Unchanged Aspirin Time Frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose pharmacokinetics Study 2, AUC(infinity): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-438F and its Metabolites (M) (M-I, M-II, M-III and M-IV-Sul) Time Frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose pharmacokinetics Study 2, AUC(0-48): Area Under the Plasma Concentration-time Curve from Time 0 to Time 48 Hours Over the Dosing Interval for TAK-438F and its Metabolites (M-I, M-II, M-III and M-IV-S | — |
Countries
Japan
Outcome results
None listed